Author of "AI Won't Automatically Accelerate Clinical Trials" in Asimov Press
How this journalist typically writes
R. Teslo as author
AI-designed drugs alone cannot significantly accelerate clinical trials because the primary bottlenecks are regulatory, operational, and biological constraints unrelated to drug candidate quality, not lack of intelligence in drug design.
“Author of "AI Won't Automatically Accelerate Clinical Trials" in Asimov Press”